Dr. Michael Deininger, chief of hematology at the Huntsman Cancer Institute at the University of Utah, explores ongoing research to fine-tune treatment for CML. Dr. Deininger discusses second-generation TKIs in frontline therapy, considerations for switching or ceasing medication, and the need to refine molecular testing into a sophisticated, reliable prognostic method.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…